Experimental drug delays type 1 diabetes onset in mid-stage trial

42

(Reuters Health) – In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more, according to results from a mid-stage study presented Sunday.

http://feeds.reuters.com/~r/reuters/healthNews/~3/hGo201uZpy8/experimental-drug-delays-type-1-diabetes-onset-in-mid-stage-trial-idUSKCN1TA0P8